---
title: "ChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program"
url: "https://aibio.space/news/chromadex-now-niagen-bioscience-adds-roth-capital-market-program/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-11-21"
section: "Financings"
tickers: "NASDAQ:NAGE"
source: "https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/cdxc-20241120.htm"
summary: "B. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents."
---

By the aibio.space news desk.

Sources

- [Niagen Bioscience, Inc. 8-K (2024-11-21)](https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/cdxc-20241120.htm)

[NAGE](https://aibio.space/companies/niagen-bioscience/)

2024-11-21

# ChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program

Tickers [NAGE](https://aibio.space/companies/niagen-bioscience/)

B. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents.

## Key facts

- **Company**: Niagen Bioscience, Inc. (NASDAQ: NAGE)

- **News type**: Financings

- **Primary source**: [Niagen Bioscience, Inc. 8-K (2024-11-21)](https://www.sec.gov/Archives/edgar/data/1386570/000162828024048830/cdxc-20241120.htm)

*A distant skyline over open water. Photo: Matt Bango, CC0, via StockSnap. The picture shows the field, not the companies named.*

ChromaDex Corporation (now Niagen Bioscience, Inc.) entered into Amendment No. 1 to its At Market Issuance Sales Agreement on November 20, 2024. The original agreement is dated June 12, 2020 and governs the company's "at-the-market" equity offering program for its common stock. An at-the-market program lets a company sell shares from time to time into the public trading market through sales agents.

The amendment makes four changes. It revises the list of sales agents to include Roth Capital Partners, LLC. It removes B. Riley Securities, Inc., formerly B. Riley FBR, Inc., as a sales agent. It updates the notice provisions to match, and it makes other conforming changes.

As a result, Raymond James & Associates, Inc. and Roth Capital Partners will continue as the sales agents under the agreement.

The 8-K was filed on November 21, 2024. The amendment itself is filed as Exhibit 1.1 to the report.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

NAGE

Niagen Bioscience, Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/chromadex-now-niagen-bioscience-adds-roth-capital-market-program/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ChromaDex (now Niagen Bioscience) adds Roth Capital to at-the-market program", 2024-11-21, https://aibio.space/news/chromadex-now-niagen-bioscience-adds-roth-capital-market-program/